Advertisement

Hormonal IUD is the major hormonal contraceptive method used among women aged 40–49 years: Data from the 2015–16 Tromsø Study, Norway

  • Merethe Bjørkås
    Affiliations
    Research Group Epidemiology of Chronic Diseases, Institute of Community Medicine, UiT the Arctic University of Norway, Tromsø N-9037, Norway
    Search for articles by this author
  • Finn Egil Skjeldestad
    Correspondence
    Corresponding author at: Department of Community Medicine, Research Group Epidemiology of Chronic Diseases, UiT The Arctic University of Norway, Tromsø N 7037, Norway.
    Affiliations
    Research Group Epidemiology of Chronic Diseases, Institute of Community Medicine, UiT the Arctic University of Norway, Tromsø N-9037, Norway
    Search for articles by this author
Published:November 23, 2022DOI:https://doi.org/10.1016/j.ejogrb.2022.11.019

      Abstract

      Objective

      This study aims to investigate hormonal contraceptive (HC) use and user characteristics in women aged 40–49 years in Norway, as little is known on use of HCs in this age segment.

      Material and methods

      This prevalence study included 2296 women aged 40–49 years who participated in the 2015–16 Tromsø Study, which collected self-reported sociodemographic information and data from a wide range of validated health questionnaires. The participants had been sexually active the last 12 months prior enrollment, were not pregnant, not trying to conceive, and had no prior fertility problems. We categorized use of HC into three groups; no HC use, hormonal IUD use and other HC use. Explanatory variables included demographic, educational, economic and general health variables. All analyses were performed in SPSS with chi-square test and logistic regression at significance level p < 0.05.

      Results

      Nearly 50 % of the study sample reported HC use with hormonal IUD use as the major method (39.5 %/40–44 years; 43.4 %/45–49 years old women). There were no differences in HC use by partner status, educational level, or BMI. Though statistically significant, we found only minor differences in HC use by occupational status, gross household income, and general health status, with higher proportions of women with no paid work, the lowest income, and poor health status reporting no HC use.

      Conclusion

      The high HC use and the minor differences found across demographic and socioeconomic parameters indicate that HC use, and hormonal IUD use in particular, is widely used among middle-aged women living in the city of Tromsø.

      Abbreviations:

      BMI (Body mass index), CI (Confidence interval), HCs (Hormonal contraceptives), IUD (Intrauterine device)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

      1. Statistics Norway. Table 07459: Population by region, sex, age and year.(Updated 27.02.2020) https://www.ssb.no/statbank/table/07459/tableViewLayout1/ (20.10.2020).

      2. Statistics Norway. Table 06831: Proportion persons by marital status, sex, age and year (Updated 23.01.2018) https://www.ssb.no/statbank/table/06831/tableViewLayout1 (20.10.2020).

        • Mercer C.H.
        • Tanton C.
        • Prah P.
        • Erens B.
        • Sonnenberg P.
        • Clifton S.
        • et al.
        Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).
        Lancet. 2013; 382: 1781-1794
        • Štulhofer A.
        • Hinchliff S.
        • Jurin T.
        • Carvalheira A.
        • Træen B.
        Successful aging, change in sexual interest and sexual satisfaction in couples from four European Countries.
        Eur J Ageing. 2019; 16: 155-165
        • Allen R.H.
        • Cwiak C.A.
        • Kaunitz A.M.
        Contraception in women over 40 years of age.
        CMAJ. 2013; 185: 565-573
        • Bieber E.J.
        • Horowitz I.R.
        • Sanfilippo J.S.
        Clinical gynecology.
        Churchill Livingstone Elsevier, New York2006
        • Hardman S.M.R.
        • Gebbie A.E.
        The contraception needs of the perimenopausal woman.
        Best Pract Res Clin Obstet Gynaecol. 2014; 28: 903-915
        • Lean S.C.
        • Derricott H.
        • Jones R.L.
        • Heazell A.E.P.
        • Bhutta Z.A.
        Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis.
        PLoS One. 2017; 12https://doi.org/10.1371/journal.pone.0186287
        • Pinheiro R.L.
        • Areia A.L.
        • Pinto A.M.
        • Donato H.
        Advanced maternal age: adverse outcomes of pregnancy, a meta-analysis.
        Acta Med Port. 2019; 32: 219-226
        • Attali E.
        • Yogev Y.
        The impact of advanced maternal age on pregnancy outcome.
        Best Pract Res Clin Obset Gynaecol. 2021; 70: 2-9
        • Varma R.
        • Sinha D.
        • Gupta J.K.
        Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - a systematic enquiry and overview.
        Eur J Obstet Gynecol Reprod Biol. 2006; 125: 9-28
        • Gupta J.
        • Kai J.
        • Middleton L.
        • Pattison H.
        • Gray R.
        • Daniels J.
        Levonorgestrel intrauterine system versus medical therapy for menorrhagia.
        N Engl J Med. 2013; 368: 128-137
        • Shargil A.A.
        Hormone replacement therapy in perimenopausal women with a triphasic contraceptive compund: a three-year prospective study.
        Int J Fertil. 1985; 30: 15-28
      3. Hernandez E, Ferriss JS. Endometrial carcinoma. I: Bieber EJ, Sanfilippo JS, Horowitz IR, Shafi MI, red. Clinical Gynecology. 2. utg. Cambridge: Cambridge University Press; 2015.

        • Ørbo A.
        • Arnes M.
        • Hancke C.
        • Vereide A.B.
        • Pettersen I.
        • Larsen K.
        Treatment results of endometrial hyperplasia after prospective D-score classification: A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
        Gynecol Oncol. 2008; 111: 68-73
        • Skjeldestad F.E.
        Use of contraception in Norway 2005.
        J Norw Med Ass. 2007; 127 (In Norwegian): 2803-2805
        • Lindh I.
        • Skjeldestad F.E.
        • Gemzell-Danielsson K.
        • Heikinheimo O.
        • Hognert H.
        • Milsom I.
        • et al.
        Contraceptive use in the Nordic countries.
        Acta Obstet Gynecol Scand. 2017; 96: 19-28
        • French R.S.
        • Gibson L.
        • Geary R.
        • Glasier A.
        • Wellings K.
        Changes in the prevalence and profile of users of contraception in Britain 2000–2010: evidence from two National Surveys of Sexual Attitudes and Lifestyles.
        BMJ Sex Reprod Health. 2020; 46: 200-209
        • Harris M.L.
        • Egan N.
        • Forder P.M.
        • Coombe J.
        • Loxton D.
        • Orueta J.F.
        Contraceptive use among women through their later reproductive years: Findings from an Australian prospective cohort study.
        PLoS One. 2021; 16
      4. The Tromsø Study. https://uit.no/research/tromsostudy. (2021-11-24).

        • Jacobsen B.K.
        • Eggen A.E.
        • Mathiesen E.B.
        • Wilsgaard T.
        • Njølstad I.
        Cohort profile: the Tromsø study.
        Int J Epidemiol. 2012; 41: 961-967
        • Skipenes V.P.
        • Skjeldestad F.E.
        Prevalence of combined contraceptive vaginal rings in Norway.
        Acta Obstet Gynecol Scand. 2016; 95: 1027-1033
        • Oddens B.J.
        • Lehert P.
        Determinants of contraceptive use among women of reproductive age in Great Britain and Germany I: demographic factors.
        J Biosoc Sci. 1997; 29: 415-435
        • Lindh I.
        • Skjeldestad F.E.
        • Heikinheimo O.
        • Hognert H.
        • Lidegaard Ø.
        • Bergh C.
        • et al.
        Reproductive changes among women in their 40s: A cross-sectional study.
        Acta Obstet Gynecol Scand. 2022; 101: 248-255
        • Skjeldestad F.E.
        Choice of contraceptive modality in Norway.
        Acta Obstet Gynecol Scand. 1994; 73: 48-52
      5. Statistics Norway. Table 08921:Population by region, age 40-49, women, education, year 2015 https://www.ssb.no/statbank/table/08921/ (20.05.2022).

        • Ørbo A.
        • Arnes M.
        • Vereide A.B.
        • Straume B.
        Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
        BJOG. 2016; 123: 1512-1519
        • Ekman J.
        • Skjeldestad F.E.
        Do Norwegian providers comply with national recommendations when prescribing combined oral contraceptives to starters?.
        A cohort study BMJ Open. 2019; 9: e027888
        • Furu K.
        • Aares E.B.
        • Hjellvik V.
        • Karlstad Ø.
        Hormonal contraceptive use in Norway, 2006–2020, by contraceptive type, age and county: A nationwide register-based study.
        Norsk Epidemiologi. 2021; 29: 55-62
        • Harlow S.D.
        • Dusendang J.R.
        • Hood M.M.
        • Woods N.F.
        Contraceptive preferences and unmet need for contraception in midlife women: where are the data?.
        Women's Midlife Health. 2017; 3: 6https://doi.org/10.1186/s40695-017-0026-6